EuroMAbNet: European Monoclonal Antibodies NetworkEuroMAbNet. European Monoclonal Antibodies Network homepage

Menu

Members

Armand Bensussan

Name of the laboratory

Immunology, Dermatologie & Oncology
INSERM U976
Hôpital Saint Louis
Equerre Bazin
1 Avenue Claude Vellefaux
75475 Paris cedex 10, France
33 153 722 081

Members of the laboratory

Members: Immunology, Dermatologie and Oncology
Head of the Unit
Researchers
Martine Bagot martine.bagot@aphp.fr
Anne Marie-Cardine anne.marie-cardine@inserm.fr
Céleste Lebbé celeste.lebbe@aphp.fr
Nicole Basset-Seguin nicole.basset-seguin@aphp.fr
Vincent Descamps vincent.descamps@aphp.fr
Sébastien Jauliac sebastien.jauliac@inserm.fr
Caroline Ram-Wolff caroline.ram-wolff@aphp.fr
Ph.D. Students
Adèle De Masson adele.demasson@aphp.fr
Charlotte Hurabielle charlotte.hurabielle@gmail.com
Technicians
Valérie Dessirier valerie.dessirier@inserm.fr
Jocelyne André jocelyne.andre@inserm.fr
Gabrielle Larcheron gabrielle.larcheron@inserm.fr
Frédéric Guaddachi frederic.gaddachi@inserm.fr
Valérie Schiavon valerie.schiavon@inserm.fr

Laboratory activity

Our laboratory is located at Saint Louis Hospital in Paris. We are working on the identification of new targets for the diagnosis and the therapy of skin diseases. Monoclonal antibodies are essential tools for determining the identification of these molecules. Dr. Armand Bensussan is the president of the French Association of Immunology, he is a member of the International HCDM (Human Cell Differentiation Molecules) Council.

Research activities

1. Physiopathology of Cutaneous T cell Lymphoma & Receptors of Innate Immunity

2. Oncogenesis of Melanoma

3. Epithelial pathophysiology, stem cells & tissue repair

Techniques available

  • Monoclonal antibody production in mice
  • Antibodies characterization
  • Multi-colour flow cytometry
  • Immunization with transfected cells

Publications (2017-present)

  • Bensussan A, Marie-Cardine A. (2018) CD160. In Encyclopedia of Signaling Molecules. Ed : S. Choi, Springer. Second Edition, p. 846-852.
  • Hurabielle C, Leboeuf C, Ram-Wolff C, Meignin V, Rivet J, Vignon-Pennamen MD, Bonnafous C, Sicard H, Fite C, Raffoux E, Arnulf B, Oksenhendler E, de Fontbrune FS, de Latour RP, Socié G, Bouaziz JD, Lebbé C, Bensussan A, Janin A, Bagot M, Battistella M. KIR3DL2 expression in patients with adult T-cell lymphoma/leukemia. Br J Dermatol. 2018 Jan 8. doi: 10.1111/bjd.16322.
  • Hocine HR, Costa HE, Dam N, Giustiniani J, Palacios I, Loiseau P, Bensussan A, Borlado LR, Charron D, Suberbielle C, Jabrane-Ferrat N, Al-Daccak R. Corrigendum: Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells. Sci Rep. 2017 Mar 16;7:44720. doi: 10.1038/srep44720.
  • Michel L, Reygagne P, Benech P, Jean-Louis F, Scalvino S, Ly Ka So S, Hamidou Z, Bianovici S, Pouch J, Ducos B, Bonnet M, Bensussan A, Patatian A, Lati E, Wdzieczak-Bakala J, Choulot JC, Loing E, Hocquaux M. Study of gene expression alteration in male androgenetic alopecia: evidence of predominant molecular signaling pathways. Br J Dermatol. 2017 Apr 12. doi: 10.1111/bjd.15577. [Epub ahead of print]
  • Roelens M, Delord M, Ram-Wolff C, Marie-Cardine A, Alberdi A, Maki G, Homyrda L, Bensussan A, Bagot M, Toubert A, Moins-Teisserenc H. Circulating and skin-derived Sézary cells: clonal but with phenotypic plasticity. Blood. 2017 Jul 31. pii: blood-2017-03-772996. doi: 10.1182/blood-2017-03-772996.
  • Garbar C, Mascaux C, Giustiniani J, Merrouche Y, Bensussan A. Chemotherapy treatment induces an increase of autophagy in the luminal breast cancer cell MCF7, but not in the triple-negative MDA-MB231. Sci Rep. 2017 Aug 3;7(1):7201. doi: 10.1038/s41598-017-07489-x.
  • Le Bouteiller P, Bensussan A. Up-and-down immunity of pregnancy in humans. F1000Res. 2017 Jul 25;6:1216. doi: 10.12688/f1000research.11690.1. eCollection 2017. Review.
  • Schmitt C, Marie-Cardine A, Bensussan A. Therapeutic antibodies to KIR3DL2 and other target antigens on cutaneous T-cell lymphomas. Front Immunol. 2017 Aug 30;8:1010. doi: 10.3389/fimmu.2017.01010. eCollection 2017. Review.
  • Battistella M, Leboeuf C, Ram-Wolff C, Hurabielle C, Bonnafous C, Sicard H, Bensussan A, Bagot M, Janin A. KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting. Blood. 2017 Oct 31. pii: blood-2017-06-792382. doi: 10.1182/blood-2017-06-792382.
  • Dam N, Hocine HR, Palacios I, DelaRosa O, Menta R, Charron D, Bensussan A, El Costa H, Jabrane-Ferrat N, Dalemans W, Lombardo E, Al-Daccak R. Human Cardiac-Derived Stem/Progenitor Cells Fine-Tune Monocyte-Derived Descendants Activities toward Cardiac Repair. Front Immunol. 2017 Oct 26;8:1413. doi: 10.3389/fimmu.2017.01413. eCollection 2017.
  • Laprevotte E, Cochaud S, du Manoir S, Lapierre M, Dejou C, Philippe M, Giustiniani J, Frewer KA, Sanders AJ, Jiang WG, Michaud HA, Colombo PE, Bensussan A, Alberici G, Bastid J, Eliaou JF, Bonnefoy N. The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway. Oncotarget. 2017 Dec 6;8(69):113360-113372. doi: 10.18632/oncotarget.23008. eCollection 2017 Dec 26.

Patents (2013-present)

  • 2016 Invariant FoxP3+ regulatory T cells and therapeutic uses thereof, US patent, 5 august 2016
  • 2016 Ex vivo generation of γδ FoxP3+ regulatory T cells and therapeutic uses thereof, US patent, 5 august 2016
  • 2016 Ex vivo generation of MHC II restricted CD4+ FoxP3+ regulatory T cells and therapeutic uses thereof, US patent, 5 august 2016
  • 2016 Immunotherapeutic uses of ex vivo generated FoxP3+ regulatory T cells, US patent, 5 august 2016
  • 2016 Monoclonal antibodies binding to the CD160 transmembrane isoform. EP 16306392.8, 25 october 2016
  • 2016 Combinations therapies for treatment of cancer. EP 16305540, 10 may 2016. Licensed to OREGA Biotech
  • 2015 Antibodies having specificity to myosin 18A and uses thereof. EP 15306108, 7 july 2015
  • 2015 Methods and pharmaceutical compositions for the treatment of BRAF inhibitor resistant melanomas. EP 15306865, 25 november 2015
  • 2013 KIR3DL2 is a biomarker and therapeutic target useful for respectively preventing and treating a subset of peripheral T-cell lymphomas. PCT/EP2013/061107, 29 may 2013
  • 2013 IL-17 antagonist antibodies. EP 13731758.2, 25 june, 2013 Licensed to OREGA Biotech

Biotechnology company

  • 2010/- OREGA-Biotech, 69000 Ecully, France
  • 2017/- Alderaan Biotechnology, 75005 Paris